Merck announced fourth-quarter sales of $11 billion worldwide – an increase of 5 percent, including a 3 percent negative impact from foreign exchange. Full-year worldwide sales for 2018 totaled $42.3 billion, marking meaningful growth with a 5 percent increase.

Fourth-quarter pharmaceutical sales increased 6 percent to $9.8 billion, largely driven by growth in oncology and vaccines. The continued strength of KEYTRUDA sales signals the company’s place as a leader in immuno-oncology.

The company anticipates full-year 2019 worldwide sales to be between $43.2 billion and $44.7 billion, including an approximately 1 percent negative impact from foreign exchange.

Merck enters 2019 with confidence in our key growth pillars of oncology, vaccines, Animal Health and select hospital and specialty care products. The company continues to invent for life with impactful results for patients and shareholders.

Take a look at the infographic below for more details on fourth-quarter and full-year results.

see more on
https://www.merck.com/about/featured-stories/2018-Q4-results.html